(480) 821-2838


(QOPI) Certification program, an affiliate of the American Society of Clinical Oncology - Learn More

Open Trials

Breast Cancer Trials:

Metastatic HER2- / ER- / PR- (Triple Negative) Breast Cancer

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer(mTNBC) – (KEYNOTE-119)
https://clinicaltrials.gov/ct2/show/NCT02555657?term=KEYNOTE-119&rank=1
For questions, please contact 480-398-7671

Advanced or metastatic HER2– ER+ Breast Cancer

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)
https://clinicaltrials.gov/ct2/show/NCT02437318?term=CBYL719C2301&rank=1
For questions, please contact 480-398-7671

Advanced or metastatic HER2 positive Breast Cancer

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)
http://clinicaltrials.gov/ct2/show/NCT01808573?term=PUMA-NER-1301&rank=1
For questions, please contact 480-398-7671

Previously treated metastatic HER2+Breast Cancer

Previously treated metastatic HER2+ Breast Cancer. A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment.
https://clinicaltrials.gov/ct2/show/NCT02492711?term=CP-MGAH22-04&rank=1
For questions, please contact 480-398-7671

Gynecologic Trials:

Previously treated serous epithelial ovarian, fallopian tube, or peritoneal cancer

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
https://clinicaltrials.gov/ct2/show/NCT02354586?term=PR-30-5020-C&rank=1
For questions please contact 480-398-7671

Leukemia Trials:

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia (UNITY-CLL)
https://clinicaltrials.gov/ct2/show/NCT02612311?term=UTX-TGR-304&rank=2
For questions, please contact 480-398-7671

Patients previously treated on another clinical trial

An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
https://clinicaltrials.gov/ct2/show/NCT02656303?term=UTX-TGR-304&rank=1
For questions, please contact 480-398-7671

Treatment for Previously Treated Chronic Lymphocytic Leukemia (CLL)

A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
https://clinicaltrials.gov/ct2/show/NCT02301156?term=UTX-IB-301&rank=1

Screening Protocol available to determine high-risk cytogenetic feature in patients with previously-treated CLL 
For questions please contact 480-398-7671

Lymphoma Trials:

Previously treated Diffuse Large B-Cell Lymphoma (DLBCL)

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02793583
For questions, please contact 480-398-7671

Lung Cancer Trials:

Small cell lung cancer (SCLC) with one prior chemotherapy

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/ Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line
https://clinicaltrials.gov/ct2/show/NCT02566993?term=PM1183-C-003-14&rank=1
For questions, please contact 480-398-7671

Second line treatment for advanced or metastatic squamous non-small cell lung cancer (NSCLC)

A Phase II Study of the Combination ofLY3023414 and Necitumumab after First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
https://clinicaltrials.gov/ct2/show/NCT02443337?term=I6A-MC-CBBE&rank=1
For questions, please contact 480-398-7671

First line treatment for metastatic/Stage IV Lung Cancer (Non-Squamous)

A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150]
https://clinicaltrials.gov/ct2/show/NCT02366143?term=GO29436&rank=1
For questions please contact 480-398-7671

First line treatment for metastatic/Stage IV Lung Cancer (Squamous)

A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131]
https://clinicaltrials.gov/ct2/show/NCT02367794?term=GO29437&rank=1
For questions please contact 480-398-7671

Melanoma Trials:

Maintenance Treatment for Patients with Resected Stage IIB, IIC, or III Melanoma

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence.
https://clinicaltrials.gov/ct2/show/NCT01546571?term=103A-301&rank=1
For questions, please contact 480-398-7671
*ENROLLMENT IS CURRENTLY ON HOLD FOR THIS TRIAL**

Multiple Myeloma

Treatment for refractory or relapsed multiple myeloma

A Phase III Study of Pomalidomide and low dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM)
https://clinicaltrials.gov/ct2/show/NCT02576977?term=MK-3475-183&rank=1
For questions, please contact 480-398-7671

Prostate Cancer Trials:

First line chemotherapy for metastatic castrate-resistant prostate cancer

A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT02111577?term=SP005&rank=1
For questions, please contact 480-398-7671

Urothelial Cancer Trials:

Advanced or metastatic urothelial carcinoma of the renal pelvis, uterer, bladder, or urethra

Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial Carcinoma
https://clinicaltrials.gov/ct2/show/NCT02853305?term=KEYNOTE-361&rank=1
For questions, please contact 480-398-7671

Show Buttons
Hide Buttons